Kathleen Francissen, Ph.D. is currently focused on developing an individualized cancer vaccine at Genentech/Roche, and is a member of the Casss board of directors. She has 20 years of experience in the biotech industry and has contributed to developing a range of recombinant protein therapeutics, including monoclonal antibodies and antibody-drug conjugates. Kathy joined Genentech in 1997 as a Scientist in Analytical Chemistry where she led a host cell proteomics research effort that was instrumental in supporting the company’s efforts to establish multi-product host cell protein assays. She has held a number of positions since joining the company, including Senior Director of CMC Regulatory, Director of Protein Analytical Chemistry, and Senior Scientist in Analytical Development. In addition to her functional leadership roles, Kathy has led a variety of cross-functional teams, including a CMC team responsible for post-approval process changes and manufacturing site transfers for one of the company’s largest products. Prior to joining Genentech, Kathy was a Visiting Scientist at the Max Planck Institute for Marine Microbiology and conducted post-doctoral studies in the U.S. Department of Energy.